Elmind Capital LP Buys Shares of 452,340 Vaxcyte, Inc. $PCVX

Elmind Capital LP purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 452,340 shares of the company’s stock, valued at approximately $26,294,524,000. Vaxcyte comprises 6.6% of Elmind Capital LP’s investment portfolio, making the stock its 5th biggest holding.

Other hedge funds have also bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its position in Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after acquiring an additional 184 shares during the last quarter. Meeder Advisory Services Inc. lifted its stake in shares of Vaxcyte by 2.9% in the 1st quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock valued at $484,000 after purchasing an additional 231 shares during the period. CWM LLC lifted its stake in shares of Vaxcyte by 9.0% in the 4th quarter. CWM LLC now owns 2,840 shares of the company’s stock valued at $131,000 after purchasing an additional 234 shares during the period. Principal Financial Group Inc. boosted its position in shares of Vaxcyte by 7.0% during the 1st quarter. Principal Financial Group Inc. now owns 5,275 shares of the company’s stock valued at $307,000 after purchasing an additional 343 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in shares of Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after purchasing an additional 364 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Down 1.3%

NASDAQ PCVX opened at $61.09 on Wednesday. Vaxcyte, Inc. has a 52 week low of $29.87 and a 52 week high of $65.00. The business has a 50 day moving average price of $56.91 and a 200-day moving average price of $55.88. The company has a market cap of $9.09 billion, a price-to-earnings ratio of -8.01 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same quarter in the prior year, the business posted ($1.22) EPS. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on PCVX shares. Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Finally, Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Vaxcyte has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Insider Buying and Selling

In other news, CEO Grant Pickering sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $55.65, for a total value of $111,300.00. Following the transaction, the chief executive officer owned 133,215 shares in the company, valued at $7,413,414.75. This trade represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harpreet S. Dhaliwal sold 17,000 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total transaction of $935,000.00. Following the transaction, the insider directly owned 76,756 shares in the company, valued at $4,221,580. The trade was a 18.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 120,646 shares of company stock valued at $6,570,810. 3.30% of the stock is owned by company insiders.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.